Directed Design, Screening and Antiglycation Activity for 3‐Substituted Thiazolium Derivatives, New Analogs of Alagebrium
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.14630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Olga N Zhukovskaya und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Physical and Organic Chemistry, Southern Federal University, Russian Federation, Rostov-on-Don, Russia. Hauptthemen laut MEDLINE: Thiazoles. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Centenarian League LLC.
Abstract (Originalsprache)
Preliminary ab initio calculations led to the synthesis of novel substituted thiazolium salts, analogs of Alagebrium, which were further explored in vitro for their potential as inhibitors of the glycation reaction utilizing three distinct assays: inhibition of fluorescent AGEs formation, anticrosslinking, and deglycation. Despite the unidirectionality of the assays, distinct differences were observed in the mechanisms of interference and activity manifestation by the compounds. The gathered data permitted the formation of hypotheses about the molecular fragments of the studied antiglycators that are of utmost significance in each assay, thereby guiding future design endeavors. Potential mechanisms of actions are discussed therein. The compound 4‐meth‐yl‐3‐[2‐(4‐methylbiphenyl‐4‐yl)‐2‐oxoethyl] thiazolium bromide displayed high activity across all three assays, establishing it as a lead compound. The cytotoxicological properties of the compounds were evaluated using LDH and MTT assays. However, the lead compound exhibited cytotoxicity, indicating the need for additional investigations aimed at decreasing toxicity while maintaining activity. The targeted thiazolium salts were synthesized through an N ‐alkylation reaction between the corresponding thiazoles and phenacyl bromides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Physical and Organic Chemistry, Southern Federal University, Russian Federation, Rostov-on-Don, Russia.
- Volgograd State Medical University, Scientific Center for Innovative Drugs, Volgograd, Russia.
- Department of Organic Chemistry, North Caucasus Federal University, Stavropol, Russia.
ORCID-Profile: Olga N Zhukovskaya, Alexandra A Kolodina, Roman Litvinov, Umida Ibragimova, Nikita Valuisky, Svetlana Sorokina, Xenia Zhukova, Diana Yu Pobedinskaya, Alexander Borisov, Denis A Babkov, Alexander A Spasov
Förderung
- Centenarian League LLC
Zitieren
APA
Zhukovskaya, O. N., Kolodina, A. A., Litvinov, R., Ibragimova, U., Valuisky, N., Sorokina, S., Zhukova, X., Pobedinskaya, D. Y., Borisov, A., Babkov, D. A., & Spasov, A. A. (2024). Directed Design, Screening and Antiglycation Activity for 3‐Substituted Thiazolium Derivatives, New Analogs of Alagebrium. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14630
Vancouver
Zhukovskaya ON, Kolodina AA, Litvinov R, Ibragimova U, Valuisky N, Sorokina S, et al. Directed Design, Screening and Antiglycation Activity for 3‐Substituted Thiazolium Derivatives, New Analogs of Alagebrium. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14630
BibTeX
@article{Zhukovskaya2024,
author = {Zhukovskaya, Olga N and Kolodina, Alexandra A and Litvinov, Roman and Ibragimova, Umida and Valuisky, Nikita and Sorokina, Svetlana and Zhukova, Xenia and Pobedinskaya, Diana Yu and Borisov, Alexander and Babkov, Denis A and Spasov, Alexander A},
title = {Directed Design, Screening and Antiglycation Activity for 3‐Substituted Thiazolium Derivatives, New Analogs of Alagebrium},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.14630}
}
EUVIMED